List of Tricor drug patents

Tricor is owned by Abbvie.

Tricor contains Fenofibrate.

Tricor has a total of 2 drug patents out of which 0 drug patents have expired.

Tricor was authorised for market use on 05 November, 2004.

Tricor is available in tablet;oral dosage forms.

Tricor can be used as adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v).

The generics of Tricor are possible to be released after 21 February, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320802 ABBVIE Methods of treatment using nanoparticulate fenofibrate compositions
Feb, 2023

(18 days from now)

US7276249 ABBVIE Nanoparticulate fibrate formulations
Feb, 2023

(18 days from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 05 November, 2004

Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v)

Dosage: TABLET;ORAL

How can I launch a generic of TRICOR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in